EDITAS MEDICINE, INC. (EDIT) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current |
| Current obligations | 68.43M USD | Liabilities, Current |
| Cash and equivalents | 181.81M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 29.83M USD | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $68.43M | $181.81M | $29.83M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $39.78M | $123.65M | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $46.25M | $146.65M | $0.00 | (m) | (m) | (m) |
| 2025-09-30 | (m) | $61.77M | $165.65M | $0.00 | (m) | (m) | (m) |
| 2025-06-30 | (m) | $65.94M | $138.54M | $39.96M | (m) | (m) | (m) |
| 2025-03-31 | (m) | $73.11M | $138.69M | $82.27M | (m) | (m) | (m) |
| 2024-12-31 | (m) | $77.22M | $131.54M | $138.37M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $72.35M | $95.83M | $169.26M | (m) | (m) | (m) |
| 2024-06-30 | (m) | $74.31M | $64.44M | $214.67M | (m) | (m) | (m) |
| 2024-03-31 | (m) | $66.49M | $69.23M | $226.94M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $63.22M | $123.65M | $199.46M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $58.60M | $82.54M | $267.08M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $54.51M | $220.82M | $211.15M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $57.16M | $129.02M | $189.42M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $60.11M | $141.52M | $202.75M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $42.29M | $210.70M | $208.91M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $36.42M | $169.40M | $283.16M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $36.50M | $210.88M | $277.48M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $46.88M | $203.52M | $296.33M | (m) | (m) | (m) |
| 2021-09-30 | (m) | $50.91M | $259.88M | $297.96M | (m) | (m) | (m) |
| 2021-06-30 | (m) | $66.02M | $337.83M | $272.72M | (m) | (m) | (m) |
| 2021-03-31 | (m) | $64.01M | $354.92M | $270.42M | (m) | (m) | (m) |
| 2020-12-31 | (m) | $58.21M | $139.68M | $262.43M | (m) | (m) | (m) |
| 2020-09-30 | (m) | $54.82M | $279.58M | $215.73M | (m) | (m) | (m) |
| 2020-06-30 | (m) | $68.15M | $485.82M | $112.90M | (m) | (m) | (m) |
| 2020-03-31 | (m) | $68.87M | $232.85M | $182.14M | (m) | (m) | (m) |
| 2019-12-31 | (m) | $59.96M | $238.18M | $218.96M | (m) | (m) | (m) |
| 2019-09-30 | (m) | $66.79M | $104.77M | $227.84M | (m) | (m) | (m) |
| 2019-06-30 | (m) | $72.87M | $210.60M | $107.33M | (m) | (m) | (m) |
| 2019-03-31 | (m) | $41.03M | $157.93M | $184.13M | (m) | (m) | (m) |
| 2018-12-31 | (m) | $35.90M | $134.78M | $234.18M | (m) | (m) | (m) |
| 2018-09-30 | (m) | $26.09M | $111.70M | $225.79M | (m) | (m) | (m) |
| 2018-06-30 | (m) | $24.02M | $131.92M | $212.16M | (m) | (m) | (m) |
| 2018-03-31 | (m) | $30.99M | $217.67M | $141.15M | (m) | (m) | (m) |
| 2017-12-31 | (m) | $36.71M | $146.63M | $182.51M | (m) | (m) | (m) |
| 2017-09-30 | (m) | $29.50M | $86.54M | $209.15M | (m) | (m) | (m) |
| 2017-06-30 | (m) | $48.69M | $144.10M | $180.70M | (m) | (m) | (m) |
| 2017-03-31 | (m) | $50.29M | $351.55M | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $33.08M | $185.32M | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | $13.76M | $199.87M | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $13.72M | $217.65M | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $10.22M | $229.20M | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $6.92M | $143.18M | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | (m) | $155.30M | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | $47.04M | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | $5.17M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | $10.62M | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | $2.01M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |